Another extended-release ADHD drug wins FDA nod

Days after Neos Therapeutics (NSDQ:NEOS) nabbed U.S. regulatory approval for its controlled-release formulation of methylphenidate, Shire (NSDQ:SHPG) said it won a nod from the FDA for its long-acting ADHD drug. The drug, Mydayis, is made up of the same active ingredient in Shire’s ADHD treatment Adderall XR – amphetamine – but it is designed to last up to 16 hours. Adderall XR is formulated to control symptoms in patients for up to 12 hours. Get the full story at our sister site, Drug Delivery Business News. The post Another extended-release ADHD drug wins FDA nod appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Food & Drug Administration (FDA) Neurological Pharmaceuticals Regulatory/Compliance Wall Street Beat neostherapeutics Shire Plc. Source Type: news

Related Links:

AbstractPurpose of ReviewTo present current data on the coexistence of attention deficit hyperactivity disorder (ADHD) and the metabolic syndrome and type 2 diabetes mellitus in adults and children and to discuss possible mechanisms.Recent FindingsEmerging data suggest that risk factors for obesity and insulin resistance such as diabetes during pregnancy and intrauterine growth failure may also have a role in the development of ADHD. Furthermore, ADHD and obesity share lifestyle factors, such as abnormal eating patterns, binge eating, and a sedentary lifestyle. ADHD is a risk factor for components of the metabolic syndrome...
Source: Current Diabetes Reports - Category: Endocrinology Source Type: research
Conclusions: PHIV+ are likely to face future physical and psychological health consequences related to the functional competence challenges they face if mental health care is not made a priority in the fight against HIV.
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - Category: Infectious Diseases Tags: Clinical Science Source Type: research
OBJECTIVES: Household environment, diet, and inattention/hyperactivity tendencies have been shown to influence children's physical and cognitive development. However, these factors are often studied independently. Therefore, there is little knowledge on th...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
BACKGROUND: There is a clinical concern that prescribing methylphenidate, the most common pharmacological treatment for attention-deficit hyperactivity disorder (ADHD), might increase the risk of psychotic events, particularly in young people with a histor...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Conclusions: The management of individuals with comorbid ADHD and anxiety disorders could be challenging for clinicians, and assessing the developmental course is crucial in order to shed light on individualised treatment. Keypoints The comorbidity between ADHD and anxiety disorders changes the clinical presentation, the prognosis and treatment of patients with ADHD across lifespan. ADHD and anxiety disorders shared common neurobiological dysfunctions but have also different neurobiological abnormalities suggesting that they are different diagnoses. These patients are less likely to benefit from cognitive behavioural treat...
Source: International Journal of Psychiatry in Clinical Practice - Category: Psychiatry Tags: Int J Psychiatry Clin Pract Source Type: research
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common diagnoses in child and adolescent mental health services, in the United States as well as in many other countries. Medication, including stimulant and non-stimulant options, is an important element of the multimodal approach to ADHD management. Stimulants are recommended as the first line pharmacological treatment.1 A recent study including data from over 150 million individuals in 13 countries showed an increase in the prevalence of ADHD medications use over the past 15 years in all countries, albeit with large variations across countries.
Source: Journal of the American Academy of Child and Adolescent Psychiatry - Category: Psychiatry Authors: Tags: In Context Source Type: research
Conclusion: Following the trial, DM+MPH was not superior to MPH alone for the treatment of children with ADHD, yet DM may potentially have negative effects on ADHD symptoms when combined with MPH.
Source: Frontiers in Psychiatry - Category: Psychiatry Source Type: research
CONCLUSIONS: Our results suggest a causal role of insomnia in autism spectrum disorder and bipolar disorder. Future disease models should include insomnia as a factor for these two disorders to develop effective interventions. More detailed mechanism studies may also be inspired by this causal inference. PMID: 31234011 [PubMed - as supplied by publisher]
Source: Journal of the Association of European Psychiatrists - Category: Psychiatry Tags: Eur Psychiatry Source Type: research
Low paid work (not strictly volunteer work) to an underserved community (e.g. scribe for ADHD students, ESL instructor). This isn't clinical work. It's also not nonclinical volunteering (because there's a low hourly rate being paid). So how do ad coms regard this? Medical scribing: This seems like shadowing except as a much more rewarding learning experience. On another thread, several posters suggested that scribing be treated as clinical experience and that additional... Which box gets checked?
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Pre-Medical - MD Source Type: forums
The start-up creating the first prescription video game for neurological conditions
Source: FT.com - Drugs and Healthcare - Category: Pharmaceuticals Source Type: news
More News: Adderall | ADHD | Amphetamine | Brain | Concerta | Methylphenidate | Neurology | Ritalin